2015, Number 1
Med Cutan Iber Lat Am 2015; 43 (1)
García OOA, Molina FE, Vera IME, Honorato GS, Mollejo VM, Schöendorff OC
PDF size: 191.98 Kb.
ABSTRACTIntroduction: The treatment of lentigo maligna (LM) in many cases is complex. The treatment of choice is surgery, but when this is not possible, we have to use alternative treatments. Topical imiquimod 5% has been used in recent years with mixed results and is currently controversial. Our objective is to describe the evolution of patients diagnosed with LM in our hospital and treated with imiquimod cream 5%, for a long period of follow-up. Observations, material and methods: All patients diagnosed with LM from 2000 through 2012 were collected and those treated with imiquimod were included in the study. The characteristics of the patients, reason for use of imiquimod, prior treatment received, used procedure, initial response, time of monitoring and presence of recurrence were studied during the follow up. Results: A total of 21 of the 23 patients completed the treatment. 76% responded to treatment with topical imiquimod. All patients who responded had a significant inflammatory skin reaction. The mean follow-up of patients was five years. During this time only one recurrence was recorded and probably is a patient misclassified as responder. Conclusions: Imiquimod should not be a treatment for LM. In selected patients, where surgery is not possible, imiquimod treatment could be tested, and if we see a significant initial inflammatory response to treatment and the absence of clinical data of LM at the end of it, is likely to get long-term remission.